163 related articles for article (PubMed ID: 30384039)
1. Prevalence and correlates of thrombosis in adults with immune thrombocytopenia: An NIS study.
Machin N; Ragni MV; Comer DM; Yabes JG
Thromb Res; 2018 Dec; 172():80-85. PubMed ID: 30384039
[TBL] [Abstract][Full Text] [Related]
2. [Antiphospholipid antibodies and the risk of thrombosis: a comparative survey between chronic immune thrombocytopenia and primary antiphospholipid syndrome].
Moulis G; Delavigne K; Huguet F; Fortenfant F; Beyne-Rauzy O; Adoue D
Rev Med Interne; 2011 Dec; 32(12):724-9. PubMed ID: 21864953
[TBL] [Abstract][Full Text] [Related]
3. Presence of Antiphospholipid Antibodies as a Risk Factor for Thrombotic Events in Patients with Connective Tissue Diseases and Idiopathic Thrombocytopenic Purpura.
Habe K; Wada H; Matsumoto T; Ohishi K; Ikejiri M; Matsubara K; Morioka T; Kamimoto Y; Ikeda T; Katayama N; Mizutani H
Intern Med; 2016; 55(6):589-95. PubMed ID: 26984073
[TBL] [Abstract][Full Text] [Related]
4. Relevance of antiphospholipid antibody profile in the clinical outcome of ITP: a single-centre study.
Frison L; Lombardi A; Caputo I; Semenzato G; Fabris F; Vianello F
Hematology; 2019 Dec; 24(1):134-138. PubMed ID: 30355275
[TBL] [Abstract][Full Text] [Related]
5. Multifocal avascular necrosis in a patient with refractory immune thrombocytopenia and antiphospholipid antibodies; case report and review of literature.
El-Gendy H; El-Gohary RM; Mahfouz S; Ahmed HMA; El Demerdash DM; Ragab G
Platelets; 2019; 30(5):664-671. PubMed ID: 30373491
[TBL] [Abstract][Full Text] [Related]
6. Management of immune thrombocytopenic purpura associated with the antiphospholipid antibody syndrome.
Leuzzi RA; Davis GH; Cowchock FS; Murphy S; Vernick JJ
Clin Exp Rheumatol; 1997; 15(2):197-200. PubMed ID: 9196875
[TBL] [Abstract][Full Text] [Related]
7. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study.
Le Guenno G; Guieze R; Audia S; Khellaf M; Michel M; Bonnotte B; Ruivard M; Godeau B
Intern Med J; 2019 Sep; 49(9):1154-1162. PubMed ID: 30816621
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.
Ruggeri M; Tosetto A; Palandri F; Polverelli N; Mazzucconi MG; Santoro C; Gaidano G; Lunghi M; Zaja F; De Stefano V; Sartori R; Fazi P; Rodeghiero F;
J Thromb Haemost; 2014 Aug; 12(8):1266-73. PubMed ID: 24942752
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory Bowel Disease and Thrombosis: A National Inpatient Sample Study.
Cohen JB; Comer DM; Yabes JG; Ragni MV
TH Open; 2020 Jan; 4(1):e51-e58. PubMed ID: 32435723
[No Abstract] [Full Text] [Related]
10. High prevalence of anti-prothrombin antibody in patients with deep vein thrombosis.
Ishikura K; Wada H; Kamikura Y; Hattori K; Fukuzawa T; Yamada N; Nakamura M; Nobori T; Nakano T
Am J Hematol; 2004 Aug; 76(4):338-42. PubMed ID: 15282665
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of thrombotic events in patients with immune thrombocytopenia.
Ito S; Fujiwara SI; Ikeda T; Toda Y; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2020 Jan; 99(1):49-55. PubMed ID: 31853702
[TBL] [Abstract][Full Text] [Related]
12. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies: A systematic review and meta-analysis.
Moulis G; Audemard-Verger A; Arnaud L; Luxembourger C; Montastruc F; Gaman AM; Svenungsson E; Ruggeri M; Mahévas M; Gerfaud-Valentin M; Brainsky A; Michel M; Godeau B; Lapeyre-Mestre M; Sailler L
Autoimmun Rev; 2016 Mar; 15(3):203-9. PubMed ID: 26708169
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of thrombopoeitin mimetics for refractory immune thrombocytopenia purpura in patients with systemic lupus erythematosus or antiphospholipid syndrome: a case series.
Lusa A; Carlson A
Lupus; 2018 Sep; 27(10):1723-1728. PubMed ID: 29673280
[TBL] [Abstract][Full Text] [Related]
14. Antiphospholipid antibodies in adults with immune thrombocytopenic purpura.
Pierrot-Deseilligny Despujol C; Michel M; Khellaf M; Gouault M; Intrator L; Bierling P; Godeau B
Br J Haematol; 2008 Aug; 142(4):638-43. PubMed ID: 18510681
[TBL] [Abstract][Full Text] [Related]
15. [Cerebral venous thrombosis and immune thrombocytopenia in a 7-year-old girl: a fortuitous association?].
Cotillon M; Lebas A; Blanc T; Schneider P; Vannier JP; Buchbinder N
Arch Pediatr; 2014 Dec; 21(12):1367-9. PubMed ID: 25445130
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis in immune thrombocytopenia - current status and future perspectives.
Swan D; Newland A; Rodeghiero F; Thachil J
Br J Haematol; 2021 Sep; 194(5):822-834. PubMed ID: 33822358
[TBL] [Abstract][Full Text] [Related]
17. Immune Thrombocytopenic Purpura as a Hemorrhagic Versus Thrombotic Disease: An Updated Insight into Pathophysiological Mechanisms.
Tărniceriu CC; Hurjui LL; Florea ID; Hurjui I; Gradinaru I; Tanase DM; Delianu C; Haisan A; Lozneanu L
Medicina (Kaunas); 2022 Feb; 58(2):. PubMed ID: 35208534
[TBL] [Abstract][Full Text] [Related]
18. Eltrombopag as steroid sparing therapy for immune thrombocytopenic purpura in systemic lupus erythematosus.
Maroun MC; Ososki R; Andersen JC; Dhar JP
Lupus; 2015 Jun; 24(7):746-50. PubMed ID: 25416695
[TBL] [Abstract][Full Text] [Related]
19. Idiopathic thrombocytopenic purpura is strongly associated with higher prevalence of aortic valve disease.
Haseefa F; Movahed MR; Hashemzadeh M; Hashemzadeh M
Ann Hematol; 2020 Sep; 99(9):2081-2084. PubMed ID: 32691113
[TBL] [Abstract][Full Text] [Related]
20. Determinants of risk for venous and arterial thrombosis in primary antiphospholipid syndrome and in antiphospholipid syndrome with systemic lupus erythematosus.
Danowski A; de Azevedo MN; de Souza Papi JA; Petri M
J Rheumatol; 2009 Jun; 36(6):1195-9. PubMed ID: 19447935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
